查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1578203

全球抗糖尿病市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测

Global Antidiabetics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 170 Pages | 商品交期: 最快1-2个工作天内

价格

全球抗糖尿病药物市场需求预计将从2023年的878亿美元达到2032年近2,612.3亿美元的市场规模，2024-2032年研究期间复合年增长率为12.88%。

抗糖尿病药物是用于稳定和控製糖尿病患者血糖水平的药物。抗糖尿病药物主要用于控製糖尿病并帮助糖尿病患者维持病情并降低糖尿病的风险。抗糖尿病药物包括胰岛素、普兰林肽、Byetta、victoza和口服降血糖（锭剂）。

市场动态

糖尿病患者发病率的上升和医疗保健支出的增加是刺激全球抗糖尿病药物市场成长的基本因素。此外，全球肥胖的流行预计将成为抗糖尿病市场的驱动力。此外，各个重要参与者正采取研发投资和产品推出等业务成长策略，推动抗糖尿病市场的成长。此外，协会和糖尿病协会为提高认识水平并提供有关糖尿病控制的信息而开展的几项宣传和教育计划运动将刺激进一步的增长。然而，胰岛素的成本可能会在一定程度上限製糖尿病市场的成长。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球抗糖尿病药物市场的各个细分市场进行了包容性评估。抗糖尿病药物产业的成长和趋势为本研究提供了整体方法。

市场区隔

抗糖尿病市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。

按药品类别范围

  • 胰岛素（长效胰岛素、预混胰岛素、速效胰岛素、人类胰岛素）
  • GLP-1 受体激动剂
  • DPP-4抑制剂
  • SGLT2 抑制剂
  • 其他的

依糖尿病类型范围

  • 类型1
  • 2型

依给药途径分类 范围

  • 口服
  • 皮下
  • 静脉

按配销通路范围

  • 网路药局
  • 医院药房
  • 零售药局

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲抗糖尿病市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。抗糖尿病市场的主要参与者包括阿斯特捷利康公司、拜耳公司、武田製药有限公司、礼来公司、勃林格殷格翰公司、百时美施贵宝公司、辉瑞公司、强生服务公司、默克公司、诺华公司股份公司。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

  • 报告说明
    • 客观的
    • 目标受众
    • 独特的销售主张 (USP) 和产品
  • 研究范围
  • 研究方法
    • 市场研究过程
    • 市场研究方法论

第 2 章：执行摘要

  • 市集亮点
  • 全球市场概况

第 3 章：抗糖尿病药物 - 产业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制
  • 机会
  • 产业动态
  • 波特五力分析
  • 市场吸引力分析
    • 按药品类别范围进行的市场吸引力分析
    • 依糖尿病类型范围进行的市场吸引力分析
    • 按管理范围分類的市场吸引力分析
    • 按配销通路范围分類的市场吸引力分析
    • 市场吸引力分析：按地区

第 4 章：价值链分析

  • 价值链分析
  • 原料分析
    • 原料清单
    • 原料厂商清单
    • 主要原物料价格走势
  • 潜在买家名单
  • 行销管道
    • 直效行销
    • 间接行销
    • 行销通路发展趋势

第 5 章：全球抗糖尿病药物市场分析：按药物类别范围

  • 按药物类别范围概述
  • 按药物类别范围进行历史和预测数据分析
  • 胰岛素（长效胰岛素、预混胰岛素、速效胰岛素、人类胰岛素）
  • GLP-1 受体激动剂
  • DPP-4抑制剂
  • SGLT2 抑制剂
  • 其他的

第 6 章：全球抗糖尿病药物市场分析：依糖尿病类型范围

  • 按糖尿病类型分類的概述范围
  • 依糖尿病类型范围进行历史和预测数据分析
  • 类型1
  • 2型

第 7 章：全球抗糖尿病药物市场分析：依管理范围划分

  • 按给药途径分類的概述 范围
  • 按管理范围分類的历史和预测资料分析
  • 口服
  • 皮下
  • 静脉

第 8 章：全球抗糖尿病药物市场分析：按分销管道范围

  • 按配销通路分類的概述范围
  • 按配销通路范围进行历史和预测资料分析
  • 网路药局
  • 医院药房
  • 零售药局

第 9 章：全球抗糖尿病药物市场分析：依地理位置

  • 区域展望
  • 介绍
  • 北美销售分析
    • 概览、历史与预测资料销售分析
    • 北美按细分市场销售分析
    • 北美按国家销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概览、历史与预测资料销售分析
    • 欧洲按细分市场销售分析
    • 欧洲按国家销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 义大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概览、历史与预测资料销售分析
    • 亚太地区按细分市场销售分析
    • 亚太地区按国家销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳洲销售分析
    • 东南亚销售分析
    • 亚太地区其他地区销售分析
  • 拉丁美洲销售分析
    • 概览、历史与预测资料销售分析
    • 拉丁美洲按细分市场销售分析
    • 拉丁美洲按国家销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概览、历史与预测资料销售分析
    • 中东和非洲按细分市场销售分析
    • 中东和非洲按国家销售分析
    • 沙乌地阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东其他地区和非洲销售分析

第 10 章：抗糖尿病药物公司的竞争格局

  • 抗糖尿病药物市场竞争
  • 伙伴关係/协作/协议
  • 併购
  • 新产品发布
  • 其他发展

第 11 章：公司简介

  • 顶级公司市占率分析
  • 市场集中度
  • AstraZeneca Plc
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Bayer AG
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Takeda Pharmaceutical Company Limited
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Eli Lilly And Company
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Boehringer Ingelheim
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Bristol-Myers Squibb
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Pfizer Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Johnson & Johnson Services Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Merck & Co. Inc
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态
  • Novartis AG
    • 公司概况
    • 公司收入
    • 产品
    • 最新动态

註 - 在公司概况中，财务详细资料和最新进展视情况而定，或对私人公司而言可能不包括在内

Product Code: VMR11218581

The global demand for Antidiabetics Market is presumed to reach the market size of nearly USD 261.23 Billion by 2032 from USD 87.8 Billion in 2023 with a CAGR of 12.88% under the study period 2024-2032.

Antidiabetic drugs are medicines introduced to stabilise and control blood glucose levels in people suffering from diabetes. Antidiabetic drugs are mainly used to manage diabetes and aid diabetic patients in maintaining their condition and lowering their risk of developing diabetes. Antidiabetic drugs include insulin, pramlintide, byetta,victoza and oral hypoglycemics (tablets).

MARKET DYNAMICS

The growing rates of diabetics and rising healthcare expenditure are the fundamental factors that are spurring the growth of the global antidiabetics market. Also, the global prevalence of obesity is expected to serve the antidiabetics market as a driver. Moreover, various significant participants are adopting business growth strategies such as R&D investments and product launches, boosting the antidiabetics market's growth. Furthermore, several campaigns for awareness and education programs created by associations and diabetes societies to raise awareness levels and provide information about diabetes control will stimulate further growth. However, the cost of insulin may limit antidiabetic market growth to some extent.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Antidiabetics. The growth and trends of Antidiabetics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Antidiabetics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class Scope

  • Insulin (Long-acting Insulin, Premix Insulin, Fast-acting Insulin, Human Insulin)
  • GLP-1 Receptor Agonists
  • DPP- 4 Inhibitors
  • SGLT2 Inhibitors
  • Others

By Diabetes Type Scope

  • Type 1
  • Type 2

By Route of Administration Scope

  • Oral
  • Subcutaneous
  • Intravenous

By Distribution Channel Scope

  • Online pharmacies
  • Hospital Pharmacies
  • Retail pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Antidiabetics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Antidiabetics market include AstraZeneca Plc, Bayer AG, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc, Novartis AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. ANTIDIABETICS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Class Scope
    • 3.7.2 Market Attractiveness Analysis By Diabetes Type Scope
    • 3.7.3 Market Attractiveness Analysis By Route of Administration Scope
    • 3.7.4 Market Attractiveness Analysis By Distribution Channel Scope
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ANTIDIABETICS MARKET ANALYSIS BY DRUG CLASS SCOPE

  • 5.1. Overview By Drug Class Scope
  • 5.2. Historical and Forecast Data Analysis By Drug Class Scope
  • 5.3. Insulin (Long-acting Insulin, Premix Insulin, Fast-acting Insulin, Human Insulin) Historic and Forecast Sales By Regions
  • 5.4. GLP-1 Receptor Agonists Historic and Forecast Sales By Regions
  • 5.5. DPP- 4 Inhibitors Historic and Forecast Sales By Regions
  • 5.6. SGLT2 Inhibitors Historic and Forecast Sales By Regions
  • 5.7. Others Historic and Forecast Sales By Regions

6. GLOBAL ANTIDIABETICS MARKET ANALYSIS BY DIABETES TYPE SCOPE

  • 6.1. Overview By Diabetes Type Scope
  • 6.2. Historical and Forecast Data Analysis By Diabetes Type Scope
  • 6.3. Type 1 Historic and Forecast Sales By Regions
  • 6.4. Type 2 Historic and Forecast Sales By Regions

7. GLOBAL ANTIDIABETICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION SCOPE

  • 7.1. Overview By Route of Administration Scope
  • 7.2. Historical and Forecast Data Analysis By Route of Administration Scope
  • 7.3. Oral Historic and Forecast Sales By Regions
  • 7.4. Subcutaneous Historic and Forecast Sales By Regions
  • 7.5. Intravenous Historic and Forecast Sales By Regions

8. GLOBAL ANTIDIABETICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL SCOPE

  • 8.1. Overview By Distribution Channel Scope
  • 8.2. Historical and Forecast Data Analysis By Distribution Channel Scope
  • 8.3. Online pharmacies Historic and Forecast Sales By Regions
  • 8.4. Hospital Pharmacies Historic and Forecast Sales By Regions
  • 8.5. Retail pharmacies Historic and Forecast Sales By Regions

9. GLOBAL ANTIDIABETICS MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE ANTIDIABETICS COMPANIES

  • 10.1. Antidiabetics Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF ANTIDIABETICS INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. AstraZeneca Plc
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Bayer AG
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. Takeda Pharmaceutical Company Limited
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Eli Lilly And Company
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Boehringer Ingelheim
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Bristol-Myers Squibb
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Pfizer Inc.
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Johnson & Johnson Services Inc.
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. Merck & Co. Inc
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Novartis AG
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Drug Class Scope (USD MN)
  • Insulin (Long-acting Insulin, Premix Insulin, Fast-acting Insulin, Human Insulin) Market Sales By Geography (USD MN)
  • GLP-1 Receptor Agonists Market Sales By Geography (USD MN)
  • DPP- 4 Inhibitors Market Sales By Geography (USD MN)
  • SGLT2 Inhibitors Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Diabetes Type Scope (USD MN)
  • Type 1 Market Sales By Geography (USD MN)
  • Type 2 Market Sales By Geography (USD MN)
  • Analysis By Route of Administration Scope (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Subcutaneous Market Sales By Geography (USD MN)
  • Intravenous Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel Scope (USD MN)
  • Online pharmacies Market Sales By Geography (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail pharmacies Market Sales By Geography (USD MN)
  • Global Antidiabetics Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Antidiabetics Report
  • Market Research Process
  • Market Research Methodology
  • Global Antidiabetics Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Drug Class Scope
  • Market Attractiveness Analysis By Diabetes Type Scope
  • Market Attractiveness Analysis By Route of Administration Scope
  • Market Attractiveness Analysis By Distribution Channel Scope
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Drug Class Scope (USD MN)
  • Insulin (Long-acting Insulin, Premix Insulin, Fast-acting Insulin, Human Insulin) Market Sales By Geography (USD MN)
  • GLP-1 Receptor Agonists Market Sales By Geography (USD MN)
  • DPP- 4 Inhibitors Market Sales By Geography (USD MN)
  • SGLT2 Inhibitors Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Diabetes Type Scope (USD MN)
  • Type 1 Market Sales By Geography (USD MN)
  • Type 2 Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration Scope (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Subcutaneous Market Sales By Geography (USD MN)
  • Intravenous Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel Scope (USD MN)
  • Online pharmacies Market Sales By Geography (USD MN)
  • Hospital Pharmacies Market Sales By Geography (USD MN)
  • Retail pharmacies Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.